Cystatin M Loss in Breast Cancer
Author Information
Author(s): Ko Eunkyung, Park Seong-Eun, Cho Eun Yoon, Kim Yujin, Hwang Jung-Ah, Lee Yeon-Su, Nam Seok Jin, Bang Saik, Park Joobae, Kim Duk-Hwan
Primary Institution: Sungkyunkwan University School of Medicine
Hypothesis
Cystatin M may be a downstream target of estrogen receptor and/or HER4, and its loss is associated with the loss of these receptors in breast cancer.
Conclusion
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Supporting Evidence
- Cystatin M loss was found in 99 (57%) of 175 patients with invasive breast cancer.
- Cystatin M loss was significantly associated with the loss of estrogen receptor (P = 0.01), progesterone receptor (P = 0.002), and HER4 (P = 0.003) in invasive breast cancers.
- Cystatin M loss occurred at a 3.57 times higher prevalence in triple-negative invasive breast cancers than in other subtypes (P = 0.01).
- The quantity of CST6 methylation was associated with estrogen receptor loss (P = 0.0002) in invasive breast cancers.
Takeaway
This study found that when a protein called cystatin M is missing in breast cancer, it often means that other important proteins are also missing, which could affect how the cancer behaves.
Methodology
The study analyzed the expression of various proteins and the methylation status of the CST6 gene in breast cancer tissues using immunohistochemistry and PCR techniques.
Limitations
The study had a small number of fresh-frozen tissues for analysis and did not analyze patient prognosis according to cystatin M loss due to a short follow-up period.
Participant Demographics
Patients aged 25 to 83 years, with 117 having ductal carcinoma in situ and 175 having invasive breast cancer.
Statistical Information
P-Value
P < 0.0001
Confidence Interval
95% CI = 1.28 to 9.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website